Clinically Meaningful EGFR Slope As a Surrogate Endpoint Differs Across CKD Stages and Slope Evaluation Periods: the CKD-JAC Study

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2025 Feb 14

PMID 39950153

Authors

Takahiro Imaizumi

Hirotaka Komaba

Takayuki Hamano

Masaomi Nangaku

Kenta Murotani

Takeshi Hasegawa

Naohiko Fujii

Kosaku Nitta

Yoshitaka Isaka

Takashi Wada

Shoichi Maruyama

Masafumi Fukagawa

Affiliations

Soon will be listed here.

Abstract

Background: The slope of estimated glomerular filtration rate (eGFR) is a promising surrogate endpoint in patients with chronic kidney disease (CKD). However, current evidence is mainly derived from Western populations with CKD stages 1-3. In addition, stage-by-stage analysis has never been formally performed.

Methods: We analyzed data from the Chronic Kidney Disease Japan Cohort Study, which included a large proportion of patients with CKD stages 4 and 5. We estimated eGFR slopes over three evaluation periods (0.5, 1, and 2 years) using mixed effects models and examined their associations with kidney failure with replacement therapy across CKD stages.

Results: Of 2713 patients with an available 1-year eGFR slope, 985 subsequently initiated kidney replacement therapy. Overall, a slower eGFR decline was strongly associated with a lower risk of subsequent kidney failure with replacement therapy. The association was pronounced with higher baseline CKD stages and attenuated with shorter evaluation periods. The estimated deceleration in eGFR decline over 1 year associated with a 20% lower risk of subsequent kidney failure with replacement therapy was 1.91 (1.60-2.37), 1.12 (1.00-1.28), and 1.06 (0.81-1.60) ml/min/1.73 m per year in patients with CKD stages 3, 4, and 5, respectively.

Conclusion: Our results support the potential of eGFR slope as a surrogate across different stages of CKD in Asians and suggest that a shorter evaluation period than 2 years may be feasible for patients with late-stage CKD. Our findings provide valuable insights for the future design of clinical trials in CKD patients, especially those with more advanced CKD.

References

Inker L, Heerspink H, Tighiouart H, Levey A, Coresh J, Gansevoort R . GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. 2019; 30(9):1735-1745. PMC: 6727261. DOI: 10.1681/ASN.2019010007. View

Levey A, Gansevoort R, Coresh J, Inker L, Heerspink H, Grams M . Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2019; 75(1):84-104. DOI: 10.1053/j.ajkd.2019.06.009. View

Looker H, Mauer M, Saulnier P, Harder J, Nair V, Boustany-Kari C . Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. J Am Soc Nephrol. 2019; 30(6):1049-1059. PMC: 6551789. DOI: 10.1681/ASN.2018111166. View

Chin M, Bakris G, Block G, Chertow G, Goldsberry A, Inker L . Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47. PMC: 5841134. DOI: 10.1159/000486398. View

Coresh J, Heerspink H, Sang Y, Matsushita K, Arnlov J, Astor B . Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019; 7(2):115-127. PMC: 6379893. DOI: 10.1016/S2213-8587(18)30313-9. View

Bauersachs J . Heart failure drug treatment: the fantastic four. Eur Heart J. 2021; 42(6):681-683. PMC: 7878007. DOI: 10.1093/eurheartj/ehaa1012. View

Vaduganathan M, Claggett B, Jhund P, Cunningham J, Ferreira J, Zannad F . Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020; 396(10244):121-128. DOI: 10.1016/S0140-6736(20)30748-0. View

Chan C, Blankestijn P, Dember L, Gallieni M, Harris D, Lok C . Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 96(1):37-47. DOI: 10.1016/j.kint.2019.01.017. View

Block G, Block M, Smits G, Mehta R, Isakova T, Wolf M . A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. J Am Soc Nephrol. 2019; 30(8):1495-1504. PMC: 6683712. DOI: 10.1681/ASN.2018101016. View

10.

Jayne D, Merkel P, Schall T, Bekker P . Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021; 384(7):599-609. DOI: 10.1056/NEJMoa2023386. View

11.

Chertow G, Vart P, Jongs N, Toto R, Gorriz J, Hou F . Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021; 32(9):2352-2361. PMC: 8729835. DOI: 10.1681/ASN.2021020167. View

12.

Lambers Heerspink H, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K . GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis. 2014; 64(6):860-6. DOI: 10.1053/j.ajkd.2014.08.018. View

13.

Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K . Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008; 31(6):1101-7. DOI: 10.1291/hypres.31.1101. View

14.

Matsushita K, Chen J, Sang Y, Ballew S, Shimazaki R, Fukagawa M . Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016; 90(5):1109-1114. DOI: 10.1016/j.kint.2016.08.003. View

15.

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

16.

Yamagata K, Nakai S, Iseki K, Tsubakihara Y . Late dialysis start did not affect long-term outcome in Japanese dialysis patients: long-term prognosis from Japanese Society for [corrected] Dialysis Therapy Registry. Ther Apher Dial. 2012; 16(2):111-20. DOI: 10.1111/j.1744-9987.2011.01052.x. View

17.

Neuen B, Weldegiorgis M, Herrington W, Ohkuma T, Smith M, Woodward M . Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression. Am J Kidney Dis. 2021; 78(3):350-360.e1. DOI: 10.1053/j.ajkd.2021.02.335. View

18.

Levey A, Inker L, Matsushita K, Greene T, Willis K, Lewis E . GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014; 64(6):821-35. DOI: 10.1053/j.ajkd.2014.07.030. View

19.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

20.

Coresh J, Grams M, Chen T . Using GFR, Albuminuria, and Their Changes in Clinical Trials and Clinical Care. Am J Kidney Dis. 2021; 78(3):333-334. DOI: 10.1053/j.ajkd.2021.04.003. View